Podcasts

Articles

SlideDownloads

Videos

Anne Delengowski, RN, MSN, AOCN, CCCTM, discusses the evolving role of the oncology nurse in clinical trial research.

Clinical Trials Continue to Propel Field of Oncology with Nurses on The Frontline

Elacestrant, an oral selective estrogen receptor degrader, may hold the potential to replace intramuscular fulvestrant injections for patients with endocrine receptor–positive, HER2-negative breast cancer. 

Oral SERD Elacestrant Shows Significant PFS Improvement in ER+/HER2– Advanced Breast Cancer

Menstrual suppression can improve outcomes and quality of life in premenopausal women undergoing hematopoietic stem cell transplant. 

Menstrual Suppression Is a Valuable Component of HSCT Care for Premenopausal Women

By certain accounts, the breast cancer awareness ribbon was actually peach before it was pink. 

Opinion: Oncology Nurses Should Know the History of the Pink Breast Cancer Awareness Ribbon

Futibatinib is now approved to treat patients with previously treated unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma. The agent comes with warnings for ocular toxicities, and hyperphosphatemia and soft tissue mineralization.

FDA Approves Futibatinib for Pretreated, Advanced or Metastatic Intrahepatic Cholangiocarcinoma with FGFR2 Rearrangements

Kristin Barber, APRN, AOCNP, FNP-BC, unpacks the FDA approval of durvalumab in combination with cisplatin and gemcitabine for patients with biliary tract cancers. 

Barber Discusses the Integration of Durvalumab/Chemotherapy Combination as New Standard of Care in Biliary Tract Cancers

Although oncology nurses are trained to show empathy and offer support, they lack the resources to adequately care for patients with acute mental health problems. 

Oncology Nurses Need Better Resources to Help Patients With Mental Health Problems

At a median follow-up of 12.4 months, patients with IDH1-mutated acute myeloid leukemia had achieved a significant improvement in event-free survival with ivosidenib/azacitidine compared with placebo.

Ivosidenib/Azacitidine Combination Achieves Favorable Responses in IDH1-Mutant AML

Karen Hande, PhD, DNP, ANP-BC, CNE, FAANP, ANEF, discusses increased patient interest in cannabinoids and how oncology nurses can steer pain management conversations to keep patients informed. 

Interest in Cannabinoids Continues to Grow Among Patients With Cancer

Following potential safety concerns with 3 PARP inhibitors, manufactures have voluntarily elected to withdraw the indications for patients with heavily pretreated patients with BRCA-mutated ovarian cancer.



All News